A Randomized, Placebo-controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus
BCB109 - EXSCEL
Patients eligible for participation must be:
* Type 2 diabetes with an HbA1c of = 7.0% and = 10.0% on stable doses of up to three oral AHAs for at least 3 months
* Patients with any level of CV risk including: history of ischemic stroke, a major clinical manifestation of coronary artery disease, myocardial infarction, surgical or percutaneous coronary revascularization procedure or coronary angiography showing at least one stenosis > 50% in a major epicardial artery or branch vessel
* Patients can also have had a history of carotid arterial disease or atherosclerotic peripheral arterial disease.